Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Sunlenca

Sunlenca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 23–24

HOS-148341 · Präparat HOS-099874

23 Medicinal product by therapeutic Effects on concentrations. Recommendation concerning areas Mean percent change in AUC, co-administration with Sunlenca Cmax CORTICOSTEROIDS (systemic) Cortisone/hydrocortisone Interaction not studied. Co-administration of Sunlenca with Dexamethasone corticosteroids whose exposures Plasma concentrations of are significantly increased by corticosteroids may be increased CYP3A inhibitors can increase the when co-administered with risk for Cushing's syndrome and lenacapavir. adrenal suppression. Initiate with the lowest starting dose and titrate Plasma concentrations of carefully while monitoring for lenacapavir may decrease when co- safety. administered with systemic dexamethasone, which may result Caution is warranted when in loss of therapeutic effect and systemic dexamethasone is development of resistance. co-administered with Sunlenca, particularly for long-term use. Alternative corticosteroids should be considered. HMG-CoA REDUCTASE INHIBITORS Lovastatin Interaction not studied. Initiate lovastatin and simvastatin Simvastatin with the lowest starting dose and Plasma concentrations of these titrate carefully while monitoring medicinal products may be for safety (e.g. myopathy). Atorvastatin increased when co-administered No dose adjustment of atorvastatin with lenacapavir. is required. Pitavastatin (2 mg single dose; d,i,l Pitavastatin: No dose adjustment of pitavastatin simultaneous or 3 days after AUC:↔ and rosuvastatin is required. lenacapavir) Cmax:↔ Rosuvastatind,i,m (5 mg single dose) Rosuvastatin: AUC:↑ 31% Cmax:↑ 57% ANTIARRHYTHMICS Digoxin Interaction not studied. Caution is warranted and therapeutic concentration Plasma concentration of digoxin monitoring of digoxin is may be increased when recommended. co-administered with lenacapavir. SEDATIVES/HYPNOTICS Midazolamd,i,n (2.5 mg single dose; Midazolam: Caution is warranted when oral; simultaneous administration) AUC: ↑ 259% midazolam or triazolam, is Cmax: ↑ 94% co-administered with Sunlenca.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) lovastatin (HOS-086157) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) digoxin (HOS-086172) dexamethasone (HOS-084535) hydrocortisone (HOS-148307) triazolam (HOS-086168) midazolam (HOS-086167) pitavastatin (HOS-125743)